Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What have we learned from recent antiplatelet trials?

J D Easton1

  • 1Department of Clinical Neurosciences, Brown University School of Medicine, Rhode Island Hospital, Providence 02903, USA.

Neurology
|September 23, 1998
PubMed
Summary

Aspirin modestly prevents vascular events like stroke and heart attack. Combination antiplatelet therapies offer enhanced protection against ischemic events and improve acute stroke outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel oral anticoagulants in secondary prevention of stroke.

Best practice & research. Clinical haematology·2013
Same author

Thrombolytic therapy increases the frequency of death and intra-cranial hemorrhage in survivors of ischemic stroke.

Evidence-based cardiovascular medicine·2005
Same author

Discussion: Reconsideration of TIA terminology and definitions.

Neurology·2004
Same author

Future perspectives for optimizing oral antiplatelet therapy.

Cerebrovascular diseases (Basel, Switzerland)·2001
Same author

Antithrombotic and thrombolytic therapy for ischemic stroke.

Chest·2001
Same author

Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.

American heart journal·2000

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Aspirin is a well-established agent for preventing vascular outcomes, reducing risk by approximately 25% compared to placebo.
  • Ticlopidine and clopidogrel have demonstrated greater efficacy than aspirin in preventing stroke or death, though ticlopidine carries significant adverse effects.
  • Dipyridamole, alone or in combination with aspirin, also shows promise in stroke prevention, with the combination being more effective than aspirin alone.

Purpose of the Study:

  • To evaluate the comparative effectiveness and safety of aspirin, ticlopidine, clopidogrel, and dipyridamole in preventing vascular events.
  • To assess the role of aspirin in the acute treatment of ischemic stroke.
  • To explore the potential of combination antiplatelet therapy for maximizing therapeutic benefits.

Related Experiment Videos

Main Methods:

  • Review of major clinical trials including CAPRIE, ESPS-2, CAST, and IST.
  • Comparative analysis of relative risk reductions for vascular outcomes (stroke, myocardial infarction, vascular death).
  • Evaluation of safety profiles and cost-effectiveness of different antiplatelet agents.

Main Results:

  • Aspirin reduces vascular risk by about 25%; however, ticlopidine and clopidogrel offer a greater risk reduction (around 12%).
  • Clopidogrel is as safe as aspirin, while ticlopidine has notable adverse effects.
  • Aspirin in acute ischemic stroke reduces early death, recurrence, and dependence, with modest but definite benefits.
  • Combination therapy with aspirin and dipyridamole showed a 13% relative risk reduction for stroke or death compared to aspirin alone.

Conclusions:

  • Aspirin provides definite but modest benefits in both acute stroke treatment and prevention.
  • Clopidogrel and dipyridamole are safe alternatives or adjuncts to aspirin, albeit at a higher cost.
  • Combination antiplatelet therapy, utilizing agents with different mechanisms, represents a promising strategy to enhance prevention of vascular events and improve stroke outcomes.